SCHEMBL3213635

SCHEMBL3213635

COCCOc1ccc(C=CC(=O)O)c(O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.45
APP P05067 1/20 0.45
BACE1 P56817 1/20 0.45
PLA2G2D Q9UNK4 1/20 0.44
POLB P06746 1/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA4 P22748 2/20 0.44
NFKB1 P19838 1/20 0.44
HDAC8 Q9BY41 1/20 0.43
MIF P14174 1/20 0.43
TRIM24 O15164 1/20 0.42
TYR P14679 1/20 0.42
TRIM33 Q9UPN9 1/20 0.42
THRB P10828 1/20 0.42
ATM Q13315 1/20 0.42
PTGER3 P43115 1/20 0.42
PTGDR Q13258 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3213628 1.00 MAPT (0.45) MAPTAPPBACE1PLA2G2DPOLB
SCHEMBL3194728 0.85 POLB (0.43) PLA2G2DPOLBHDAC8THRBATM
SCHEMBL3194718 0.85 POLB (0.43) PLA2G2DPOLBHDAC8THRBATM
SCHEMBL766043 0.82 TRIM24 (0.62) MAPTAPPBACE1CA1CA2
SCHEMBL766042 0.82 TRIM24 (0.62) MAPTAPPBACE1CA1CA2
SCHEMBL30194379 0.82 TRIM24 (0.62) MAPTAPPBACE1CA1CA2
SCHEMBL3208404 0.81 HDAC8 (0.64) MAPTAPPPLA2G2DHDAC8PTGER3
SCHEMBL3208391 0.81 HDAC8 (0.64) MAPTAPPPLA2G2DHDAC8PTGER3
SCHEMBL766034 0.81 PELI1 (0.52) APPKDM4EALDH1A1KMT2A
SCHEMBL3204682 0.81 TYR (0.65) MAPTAPPPOLBMIFTRIM24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041892-A1 Therapeutic agent for diabetes ABE HIDENORI 2010-02-18 US disclosed
US-20090270631-A1 Therapeutic agent for diabetes ABE HIDENORI 2009-10-29 US disclosed
EP-1912645-A2 THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2008-04-23 EP disclosed
US-20080009530-A1 Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-10 US disclosed
WO-2007018314-A2 THERAPEUTIC AGENT FOR DIABETES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270631-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 MAPT 4588/4885APP 3197/4885BACE1 2908/4885
US-20080009530-A1 Therapeutic Agent for Diabetes FABP4, SLC5A1, SLC5A2 MAPT 4612/4885APP 3588/4885BACE1 3658/4885
US-20100041892-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 MAPT 4588/4885APP 3197/4885BACE1 2908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.